Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Launched by JOHNS HOPKINS UNIVERSITY · Feb 15, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of different types of alcohol treatment after a liver transplant for people suffering from alcoholic hepatitis. The focus is on comparing a new approach that combines personal support and computer-based treatment to standard care. Researchers want to see how these treatments affect alcohol use, mood, quality of life, and survival rates after the transplant. This study is important because it aims to find better ways to help patients avoid drinking alcohol again after their transplant, which can have serious health consequences.
To participate in this trial, you need to be between 65 and 74 years old, speak English, and be able to provide informed consent, meaning you understand what the study involves. Unfortunately, if you are too ill or have significant mental health challenges, you won't be eligible. If you join the study, you can expect to receive either the new treatment or standard care, and your progress will be monitored over time. This research could lead to more effective treatments for individuals recovering from alcohol use disorder after liver transplants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English speaking
- Exclusion Criteria:
- • too medically/psychiatrically ill to participate
- • not able to provide informed consent due to cognitive impairment
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Mary E McCaul, PhD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials